Tenax Therapeutics (TENX) Non-Current Assets (2011 - 2024)
Tenax Therapeutics (TENX) posted quarterly Non-Current Assets of $1117.0 for Q3 2024, down 80.82% year-over-year from $5823.0 in Q4 2023, and little changed on a QoQ basis from $1117.0 in Q2 2024.
Tenax Therapeutics (TENX) Non-Current Assets (2011 - 2024) Analysis & Trends
Tenax Therapeutics has reported Non-Current Assets for 13 years, with the latest figure at $1117.0 in Q3 2024.
- Non-Current Assets for Q3 2024 came in at $1117.0, down 80.82% year-over-year; the trailing twelve-month figure through Jun 2025 was $1117.0 (down 87.67% YoY), and the FY2023 annual result was $1000.0, down 99.49% from the prior year.
- Non-Current Assets steadied at $1117.0 in Q3 2024, from $1117.0 in the prior quarter.
- Over five years, Non-Current Assets peaked at $352954.0 in Q2 2021 and troughed at $1000.0 in Q4 2023.
- A 5-year average of $130338.9 and a median of $99181.0 in 2020 frame the typical range for Non-Current Assets.
- The widest annual swing landed in 2022, when Non-Current Assets soared 556.27%; it then tumbled 99.49% in 2023.
- A 5-year view of Non-Current Assets shows it stood at $73185.0 in 2020, then surged by 314.34% to $303235.0 in 2021, then slumped by 35.28% to $196244.0 in 2022, then tumbled by 99.49% to $1000.0 in 2023, then increased by 11.7% to $1117.0 in 2024.
- Per Business Quant data, the three most recent Non-Current Assets figures were $1117.0 in Q3 2024, $1117.0 in Q2 2024, and $1117.0 in Q1 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 14.88 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 23.28 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 1.96 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 5.15 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 1.96 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 938.60 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 6.80 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 468.65 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 18.06 Bn |
| 10 | Tenax Therapeutics | 78.47 Mn | 78.47 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2024 | 1,117.00 |
| Jun 30, 2024 | 1,117.00 |
| Mar 31, 2024 | 1,117.00 |
| Dec 31, 2023 | 1,000.00 |
| Sep 30, 2023 | 5,823.00 |
| Jun 30, 2023 | 6,792.00 |
| Mar 31, 2023 | 6,749.00 |
| Dec 31, 2022 | 196,244.00 |
| Sep 30, 2022 | 225,427.00 |
| Jun 30, 2022 | 253,941.00 |
| Mar 31, 2022 | 281,948.00 |
| Dec 31, 2021 | 303,235.00 |
| Sep 30, 2021 | 328,367.00 |
| Jun 30, 2021 | 352,954.00 |
| Mar 31, 2021 | 42,962.00 |
| Dec 31, 2020 | 73,185.00 |
| Sep 30, 2020 | 99,181.00 |
| Jun 30, 2020 | 138,792.00 |
| Mar 31, 2020 | 156,488.00 |
| Dec 31, 2019 | 184,442.00 |